Stock screenerAll disclosures →
EDGAR →
MPLT
Conviction 0HealthcareScan · Thu, Sep 24, 2026MapLight Therapeutics, Inc. (MPLT) closed at $10.81 (+0.37%) on Sep 24, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 31, -72.8% from its 52-week high, -35.5% year to date. Sector: Healthcare · Biotechnology.
MPLT$10.81+0.37%
ResistanceSupportVol 14Insider buyInsider sell4
12
14
Vol MA14 585.27K
Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24
Price10.81
Change+0.37%
Gap-1.67%
Rel volume0.92×
Avg volume606.65K
Avg $ vol7.44M
SMA 2012.40
SMA 5015.70
SMA 20021.80
Price vs 50-31.15%
Price vs 200-50.42%
MA stackbearish
50/200 cross—
Supertrenddown · 13.18
RSI (14)31
MACD hist0.08
MACD cross—
Stoch %K / %D17 / 14
ADX (14)33
+DI / −DI12 / 30
RSI divergenceBullish
MACD divergenceBullish
ATR %9.56%
ADR %6.84%
52w high39.80
52w low9.91
From 52w high-72.84%
Above 52w low+9.14%
New 52w highNo
SqueezeOff
Bollinger width36.27%
%B0.15
Donchian pos16.63%
Donchian high14.22
Donchian low10.13
AVWAP (52w high)15.59
vs AVWAP high-30.66%
AVWAP (52w low)12.49
vs AVWAP low-13.46%
OBV trendDown
Chaikin MF (20)-0.07
Today vs 20d0.92×
Avg vol (14d)585.27K
Avg vol (20d)606.65K
Avg $ vol (20d)7.44M
Market cap458.74M
RS Rating—
RS 3m (vs SPY)-70.67%
RS 6m (vs SPY)-57.23%
RS line new highNo
Trend template—
Technical rank9.7
1 week-4.51%
1 month-13.80%
3 months-66.18%
6 months-40.41%
1 year—
YTD-35.54%
P/E-2.85
P/B1.32
P/S—
P/FCF-3.31
EPS-18.56
Div yield—
ROE-46.27%
ROA-43.75%
Debt/Eq—
Current16.52
EV/EBITDA—
Gross margin—
Net margin—
Rev growth—
EPS growth-107.72%
Price target28.00
Target upside159.02%
Analyst ratingBuy
Institutional43.79%
Ent. value387.1M
Revenue—
Net income-60.19M
Gross profit—
Free cash flow-138.61M
IndustryBiotechnology
ExchangeNasdaq
Shares out42.62M
Employees133
ListedMon, Oct 27, 2025
Free float18.66M
Float %41.1%
Short interest3.43M
Days to cover5.7d
Short volume62.2%
Squeeze score77 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$1.32 vs −$1.40
Last surprise+5.7% beat
Setup gradeD
Conviction0 / 100
Pattern quality—
Tech rank9.7 / 100
Group rank59 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance13.98
Support10.51
Days since event—
Candle confirm—
Financials as of Tue, Jun 30, 2026 · quarterly.
Recent news
- MapLight Therapeutics, Inc.: Resale prospectusSEC EDGAR · Wed, Sep 23, 2026
Congress activity
Disclosed STOCK Act trades in MPLT
No recent disclosed trades by Congress in MPLT. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in MPLT
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Foff Erin Pennock Chief Medical Officer · Employee Stock Option (right to buy) · 2026-08-17 | Grant | 54.24K | — | 2026-08-17 | 2026-08-19 |
GILLIS JONATHAN CAO and Interim CFO · Voting Common Stock · 2026-08-17 | Grant | 6.02K | — | 2026-08-17 | 2026-08-19 |
Foff Erin Pennock Chief Medical Officer · Voting Common Stock · 2026-08-17 | Grant | 13.36K | — | 2026-08-17 | 2026-08-19 |
GILLIS JONATHAN CAO and Interim CFO · Voting Common Stock · 2026-08-17 | Grant | 2.22K | — | 2026-08-17 | 2026-08-19 |
GILLIS JONATHAN CAO and Interim CFO · Employee Stock Option (right to buy) · 2026-08-17 | Grant | 24.45K | — | 2026-08-17 | 2026-08-19 |
GILLIS JONATHAN CAO and Interim CFO · Employee Stock Option (Right to Buy) · 2026-08-17 | Grant | 2.81K | — | 2026-08-17 | 2026-08-19 |
Hanson Kristopher General Counsel · Voting Common Stock · 2026-08-17 | Grant | 7.73K | — | 2026-08-17 | 2026-08-19 |
Hanson Kristopher General Counsel · Employee Stock Option (right to buy) · 2026-08-17 | Grant | 31.39K | — | 2026-08-17 | 2026-08-19 |
Kreitzer Anatol Chief Discovery Officer · Voting Common Stock · 2026-08-17 | Grant | 6.02K | — | 2026-08-17 | 2026-08-19 |
Kreitzer Anatol Chief Discovery Officer · Employee Stock Option (right to buy) · 2026-08-17 | Grant | 24.45K | — | 2026-08-17 | 2026-08-19 |
SEC filings
EDGAR filings in MPLT · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.